Day One Biopharmaceuticals, Inc. (DAWN)
Apr 21, 2026 - DAWN was delisted (reason: acquired by Servier)
21.53
+0.04 (0.19%)
Inactive · Last trade price on Apr 22, 2026
DAWN Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for DAWN stock had an average target of $24.43, with a low estimate of $21.5 and a high estimate of $34.
Price Target: $24.43 (+13.47%)
Analyst Consensus: Buy
Price Target
Analyst Ratings
The average analyst rating for DAWN stock from 8 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
245.23M
from 158.18M
Increased by 55.03%
Revenue Next Year
314.20M
from 245.23M
Increased by 28.12%
EPS This Year
-0.89
from -1.04
EPS Next Year
-0.20
from -0.89
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 265.0M | 362.8M | ||||||
| Avg | 245.2M | 314.2M | ||||||
| Low | 222.8M | 272.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 67.5% | 47.9% | ||||||
| Avg | 55.0% | 28.1% | ||||||
| Low | 40.8% | 11.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.43 | 0.37 | ||||||
| Avg | -0.89 | -0.20 | ||||||
| Low | -1.98 | -0.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |